Newsfeeds Archive - Spark Newswire

3 minute read

Psyched: LSD For Major Depression, Canada’s Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More

April 24, 3:57 PM

LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a treatment of Major Depressive Disorder (MDD).

AWKNF

2 minute read

Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism

By Lara Goldstein

April 20, 9:02 AM

The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC: NMLSF) has started <

NMLSF

6 minute read

Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More

By Lara Goldstein

February 21, 6:19 PM

Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and added to the list of measures calling for some sort of psychedelics legalization, while some of the already filed ones continue progressing and others get a thumbs down.

AGNPF

2 minute read

Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder

By Lara Goldstein

February 14, 2:37 PM

Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a genetic disorder.

KONEF

2 minute read

First-Ever Clinical Trial On Magic Mushroom Therapy For Autism’s Genetic Cause Receives Approval

By Lara Goldstein

December 27, 1:47 PM

The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a No Objection letter and is set to proceed with the first-ever Phase 2a clinical trial on the magic mushrooms therapy for this condition.

KONEF

4 minute read

Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal’s Decrim Project

By Lara Goldstein

December 6, 3:20 PM

Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and further guidance for pre-clinical research and studies with young participants.

AWKNF

2 minute read

Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial

By Lara Goldstein

November 17, 3:48 PM

Psychedelics company Wellbeing Digital Sciences Inc. (OTC: KONEF)’s subsidiary KGK Science Inc. has entered into a research services agreement with Canadian-based biotech Nova Mentis Life Science Corp.

KONEF

4 minute read

Psyched: Autopsy Reveals Death By Ketamine, LSD-Like Drugs Without Hallucinations, DEA & Right To Try Psilocybin

By Lara Goldstein

September 30, 4:15 PM

Amended Autopsy Confirms Elijah McClain Died From Ketamine Injected By Paramedics Called By Cops

ATAI

1 minute read

Magic Mushroom In A Pill? New Microdose Plans Enter Clinical Studies: Here’s What Scientists Want To Learn

By Lara Goldstein

September 29, 2:36 PM

Nova Mentis Life Science Corp. (OTCQB: NMLSF), a biotech company focused on creating psilocybin-based therapeutics produced 1.5 mg psilocybin microdose capsules compliant with the chemistry, manufacturing and controls (CMC) published guidelines.

NMLSF